BioSpace News Archive

Today Syntegra and Nashville Biosciences, a wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), announced a collaboration to accelerate data driven innovation and research for drug discovery and development.

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company’s lead product candidate, will be presented in a poster at the American Society for Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting

BioReference Laboratories, Inc., an OPKO Health company, announced its renewal as the COVID-19 testing provider for Major League Soccer, which began on April 17 along with the 2021 MLS season.

It has been more than a year since the COVID-19 disease took the whole world by storm, and people are still getting infected. There is no doubt that the COVID-19 disease pandemic has had an unbearable and adverse impact on underserved communities with insufficient COVID-19 test access and long wait times for results

ResMed (NYSE: RMD, ASX: RMD) today announced Brett Sandercock, chief financial officer, will present virtually at the Macquarie Australia Conference on Wednesday, May 5, 2021, beginning at approximately 8:45 a.m. (Australian Eastern Standard Time) via video webcast.

GeneThera announced today that it has entered into a partnership agreement with Cumming Corporation, a privately held international project consulting firm, specialized in the healthcare sector company.

Insightec®, a global healthcare company focused on creating the next generation of patient care, announced today that Aetna is the first national payor to cover MR-guided Focused Ultrasound for treating medication-refractory Essential Tremor.

Nikon Instruments Inc., innovator of advanced microscope systems, today announced the release of the next generation confocal microscope series, AX and AX R.

Impact Biosystems, the Boston-based company that develops adaptive hardware and software services in the sports recovery space, closed $4.5m in new funding, co-led by Will Ventures and NextView Ventures.

Oxford Immunotec, a global, high-growth diagnostics company part of PerkinElmer (NYSE: PKI), today announced that its T-SPOT®Discovery SARS-CoV-2 kit will be used for T cell testing in the UK Com-COV trial.